Title: Melatonin and/or rowatinex attenuate streptozotocin-induced diabetic renal injury in rats


Authors: Tarek K Motawi1, Samia A Ahmed2, Manal A Hamed2, Shohda A El-Maraghy1, Wessam M Aziz2


Institutions: 1Biochemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt; 2Therapeutic Chemistry Department, National Research Centre, Dokki, Cairo, Egypt.


Abstract: The study aimed to explore the prophylactic effect of melatonin, rowatinex; a naturally occurring renal drug, and its combination on diabetic nephropathy in type 2 diabetic rats. Diabetes was induced by intraperitoneal injection of a single dose of streptozotocin (50 mg/g body weight). Three days before diabetes induction, rats were daily treated with melatonin, rowatinex and their combination continuously for 8 weeks. Evaluation was done through measuring blood urea nitrogen (BUN), serum uric acid, serum creatinine, urine creatinine, creatinine clearance, nitric oxide (NO), malondialdehyde (MDA), superoxide dismutase (SOD), glutathione (GSH), total antioxidant capacity (TAC), kidney injury molecule-1 (KIM-1), heat shock protein-70 (HSP-70), caspase-3, transforming growth factor β1 (TGFβ1), DNA degradation by the comet assay and total protein contents. Histopathologic study was also done for the kidney and the pancreas. Drastic changes in all measured parameters of the diabetic rats were observed. Treatment with melatonin and rowatinex showed amelioration to variable degrees. In conclusion, melatonin showed the most potent effect on protecting rats from deleterious action of diabetic nephropathy followed by its combination with rowatinex.


Keywords: diabetic nephropathy, melatonin, rowatinex, histopathology


Full Text: JBR-2016-0028.pdf


J Biomed Res published on 28 February 2017, doi:10.7555/JBR.31.20160028